Efgartigimod

Phase 1/2Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Epidermolysis Bullosa (EB)

Conditions

Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa

Trial Timeline

Jul 1, 2025 → Oct 1, 2026

NCT ID

NCT07011589

About Efgartigimod

Efgartigimod is a phase 1/2 stage product being developed by Argenx for Epidermolysis Bullosa (EB). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07011589. Target conditions include Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04777734	Pre-clinical	Completed	—	—	Generalized Myasthenia Gravis
NCT07011589	Phase 1/2	Recruiting	Jul 1, 2025	Oct 1, 2026	Epidermolysis Bullosa (EB)
NCT06860633	Approved	Recruiting	Mar 6, 2025	Dec 31, 2026	Myasthenia Gravis Crisis
NCT06298565	Pre-clinical	Recruiting	Nov 4, 2024	Jun 1, 2034	Myasthenia Gravis
NCT06299748	Pre-clinical	Recruiting	Nov 30, 2023	Dec 1, 2033	Myasthenia Gravis
NCT06203457	Phase 2	Completed	Nov 29, 2023	Feb 3, 2025	Primary Sjögren's Syndrome
NCT05918978	Phase 2	Terminated	Jun 20, 2023	Aug 15, 2024	Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
NCT04274452	Phase 3	Withdrawn	Jun 29, 2020	Sep 1, 2021	Primary Immune Thrombocytopenia (ITP)
NCT04225156	Phase 3	Completed	Jun 2, 2020	Mar 11, 2026	Primary Immune Thrombocytopenia
NCT04188379	Phase 3	Completed	Dec 16, 2019	Feb 3, 2022	Primary Immune Thrombocytopenia

Competing Products

13 competing products in Epidermolysis Bullosa (EB)

See all competitors

Product	Company	Stage	Hype Score
KB803 + Placebo	Krystal Biotech	Phase 3	74
Topical beremagene geperpavec + Placebo gel	Krystal Biotech	Phase 1/2	38
Topical Beremagene Geperpavec	Krystal Biotech	Phase 3	74
Open Label Topical Beremagene Geperpavec (B-VEC)	Krystal Biotech	Phase 3	74
SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%)	Amicus Therapeutics	Phase 2	49
SD-101-6.0 cream + Placebo (SD-101-0.0) cream	Amicus Therapeutics	Phase 3	74
SD-101-6.0 cream	Amicus Therapeutics	Phase 3	74
SD-101 dermal cream (6%)	Amicus Therapeutics	Phase 2	49
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets	Abeona Therapeutics	Phase 1/2	33
EB-101	Abeona Therapeutics	Phase 3	69
EB-101 Surgical application of RDEB wounds	Abeona Therapeutics	Phase 3	69
VPD-737	Vyne Therapeutics	Phase 2	44
Serlopitant Tablet + Placebo Oral Tablet	Vyne Therapeutics	Phase 2	44

Other Products from Argenx

IV efgartigimodApproved

EfgartigimodApproved

Efgartigimod PH20 SCApproved

Efgartigimod IVPhase 3